Viewing Study NCT03773666


Ignite Creation Date: 2025-12-24 @ 4:31 PM
Ignite Modification Date: 2025-12-25 @ 2:23 PM
Study NCT ID: NCT03773666
Status: COMPLETED
Last Update Posted: 2022-09-13
First Post: 2018-12-08
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Sponsor: Dana-Farber Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module